Trial Profile
A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAMILLA
- 20 Jan 2024 Results (n=29 of the phase II G/E adenocarcinoma cohort) assessing safety and efficacy of of cabozantinib (cabo) plus durvalumab (durva) in chemotherapy refractory microsatellite stable patients with advanced gastric and esophageal adenocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium
- 11 Jul 2023 Planned End Date changed from 30 Jun 2024 to 30 Dec 2025.
- 11 Jul 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.